Last close · 16 Oct 2026
Rs 61.66 -0.61%
Valuation · at the close on 16 Oct 2026
Citi Pharma Ltd. (CPHL) valuation
At Rs 61.66 (close on 16 Oct 2026) CPHL trades at 17.8× earnings (FY2026), above its five-year average of 14.1× and above the Pharmaceuticals median of 12.5×. The shares are priced at 1.30× book value (sector median 3.14×). Enterprise value of Rs 16.9 bn is 7.9× EBITDA.
- P/E · today
- 17.8×
- FY2026
- 5-yr average14.1× Sector median12.5×
- P/B · today
- 1.30×
- FY2026
- 5-yr average1.49× Sector median3.14×
- EV/EBITDA · today
- 7.9×
- 5-yr average7.8× Sector median6.7×
- Dividend yield · today
- 0.0%
- FY2026
- 5-yr average3.8% Payers' median4.6%
Market value Rs 14.1 bn at Rs 61.66. Sector medians use the latest close of 14 Pharmaceuticals companies; P/E and P/B only where earnings / book value are positive; the yield median covers dividend payers only. Not investment advice.
Valuation history
At each fiscal year-end price.
| Rs bn | FY2026 Jul 2025 – Jun 2026 | FY2025 Jul 2024 – Jun 2025 | FY2024 Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 | FY2021 Jul 2020 – Jun 2021 | FY2020 Jul 2019 – Jun 2020 |
|---|---|---|---|---|---|---|---|
| Market capitalisation | 17.8 | 19.2 | 6.5 | 4.9 | 7.5 | — | — |
| Enterprise value | 20.6 | 20.6 | 6.6 | 5.1 | 6.4 | — | — |
| Share price (period end) Rs | 77.87 | 83.97 | 28.50 | 21.34 | 32.64 | — | — |
| P/E (diluted) | 22.51× | 21.51× | 7.81× | 7.41× | 11.33× | — | — |
| Price to book | 1.64× | 1.77× | 1.16× | 0.91× | 1.58× | — | — |
| Price to sales | 1.26× | 1.46× | 0.52× | 0.39× | 0.76× | — | — |
| EV / EBITDA | 9.59× | 11.61× | 4.89× | 4.09× | 5.98× | — | — |
| EV / Sales | 1.46× | 1.56× | 0.53× | 0.42× | 0.65× | — | — |
| Dividend yield (gross) | 4.5% | 3.9% | 8.8% | 0.0% | 0.0% | — | — |
| Free cash flow yield | (3.1%) | (2.5%) | 11.8% | (26.3%) | (12.5%) | — | — |
| PEG ratio | (1.97×) | 3.06× | 0.29× | (162.97×) | (0.36×) | — | — |
| P/E (diluted, normalised) | 22.51× | 21.51× | 7.81× | 7.62× | 11.33× | — | — |
| Price to book — 5-year average | 1.49× | — | — | — | — | — | — |
| EV / EBITDA — 5-year average | 7.81× | — | — | — | — | — | — |
| Dividend yield — 5-year average | 3.8% | — | — | — | — | — | — |
CPHL valuation: frequently asked questions
What is CPHL's P/E ratio?
At the closing price of Rs 61.66 on 16 Oct 2026, CPHL trades at a P/E of 17.8× based on EPS of Rs 3.46 (FY2026).
What is CPHL's book value per share?
Citi Pharma Ltd.'s book value per share was Rs 47.42 at the end of FY2026. The shares trade at 1.30× book value.
Information only, not investment advice.